Disclaimer: This article is for informational and educational purposes only. It is based on published scientific literature and does not constitute medical advice. All products referenced are for laboratory research use only and are not intended for human or animal use.
CJC-1295 / Ipamorelin Blend: What Researchers Need to Know
CJC-1295 / Ipamorelin · Published February 26, 2026 · Updated May 18, 2026 · 7 min read
Quick Answer
CJC-1295/Ipamorelin blend pairs a stabilized GHRH analog with a selective ghrelin receptor agonist for research on combined growth hormone release pathways. This guide covers the rationale, mechanism, and laboratory handling considerations for studying dual-receptor pituitary signaling in preclinical models. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Frequently Asked Questions
What is CJC-1295 in research contexts?
+
CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.
What does the CJC-1295/Ipamorelin blend achieve in research?
+
The blend produces synergistic GH release through complementary mechanisms: CJC-1295 activates the GHRH receptor while Ipamorelin selectively activates the ghrelin receptor (GHS-R1a). The combined cAMP and calcium signaling on somatotrophs amplifies pulsatile GH secretion beyond either alone.
How is dosing structured in CJC-1295/Ipamorelin research?
+
Most rodent protocols use subcutaneous administration with weight-normalized dosing, often timed before sleep to align with endogenous nocturnal GH pulses. Ratios are typically formulated to deliver each peptide at its individually effective concentration.
Is CJC-1295 approved for human use?
+
No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Glossary
Key terms used in this article.
- GHRH
- Growth hormone-releasing hormone, the hypothalamic peptide that stimulates pituitary growth hormone release.
- DAC (Drug Affinity Complex)
- A maleimidopropionic acid linker on CJC-1295 that covalently binds serum albumin to extend half-life.
- Pulsatile Release
- The episodic, rhythmic secretion pattern characteristic of growth hormone from the anterior pituitary.
- Pituitary Somatotroph
- The anterior pituitary cell type that synthesizes and secretes growth hormone.
- IGF-1
- Insulin-like growth factor 1, the primary downstream mediator of growth hormone action, produced largely in the liver.
- GHS-R1a
- Growth hormone secretagogue receptor 1a, the ghrelin receptor through which ipamorelin signals.
- GHRP
- Growth hormone-releasing peptide, a class of synthetic ghrelin receptor agonists that stimulate GH release.
- Ghrelin
- The endogenous 28-amino-acid acylated peptide hormone that activates GHS-R1a and stimulates appetite and GH release.
More from the Blog
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
